[QUISEL, John, BECONI, Maria, ROBINETTE, Steven, MACDONALD, Brian] 321 Arsenal Street, Suite 101, Watertown, MA 02472, US

[Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, Jennifer M. Perez] US MA Watertown Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.

[BECONI MARIA, WU MIN, HONG VU] US The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT 1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating a hepatic porphyria, and related syndromes thereof.

[Maria Beconi, Daniel Elbaum, Steven Harper, Savina Malancona] US CA San Diego Compounds having the following formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurological disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in the treatment of neurological disorders, also are provided.

[QUISEL, John, SAVAGE, William, Jacob, BECONI, Maria, Gabriela, HONG, Vu, WU, Min, XIANG, Yi, REDDY, Pavan] 321 Arsenal Street, Suite 101Watertown, MA 02472 The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating polycythemia, and related syndromes thereof.

[MACDONALD, Brian, Richard, SAVAGE, William, Jacob, BECONI, Maria, Gabriela, WU, Min, REDDY, Pavan] 321 Arsenal Street, Suite 101Watertown, MA 02472 The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating anemia associated with a ribosomal disorder, and related syndromes thereof.

[Bernard Mayer Ravina, Maria G. Beconi-Barker, Judith Dunn, Mark Rogge] US MA Cambridge The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and/or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

[DOMINGUEZ, Celia, MUÑOZ-SANJUAN, Ignacio, BEAUMONT, Vahri, BECONI, Maria, BÜRLI, Roland, W., HAUGHAN, Alan, F., LUCKHURST, Christopher, A., WALL, Michael, RAPHY, Gilles, THOMAS, Beth]

[MACDONALD BRIAN, QUISEL JOHN, SAVAGE WILL, YANG HUA, YU JONATHAN, WU MIN, BECONI MARIA, PEREZ JENNIFER, MUELLER BERNHARD, POPP ANDREAS] ;; Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and/or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.

[MUELLER BERNHARD, POPP ANDREAS, PEREZ JENNIFER M, YANG HUA, MACDONALD BRIAN, BECONI MARIA, QUISEL JOHN, WU MIN, SAVAGE WILL, YU JONATHAN] US Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and/or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.